What’s it like to live with bvFTD? researchers ask patients directly
NCT ID NCT04060082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study interviewed 26 adults who either have behavioral variant frontotemporal dementia (bvFTD) or carry a gene that puts them at risk. The goal was to learn how the condition affects daily life, emotions, and coping. No treatment or medication was tested—just listening and gathering insights.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
26 people
The number who actually took part.
- Started
-
Jun 2019
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants for the study will be recruited through the University of Pennsylvania and ClinicalTrials.gov. Previously, participants were also recruited through Johns Hopkins University, through a dementia research study at the National Institutes of Health, through the Penn FTD Center Caregiver Conference, and through through a private Facebook group for individuals with C9orf72 mutations.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 18 years of age or older * Speak fluent English * People with bvFTD must have been diagnosed with behavioral variant frontotemporal degeneration (bvFTD) * People with a known genetic risk factor for bvFTD must have an identified disease-causing change in a gene that is known to cause bvFTD, such as in C9ORF72, MAPT, GRN, VCP, TARDBP, CHMP2B, or another gene that has been identified as causing FTD in the family * The diagnosis or genetic testing results must have been disclosed to the participant at least two months prior to study enrollment Exclusion Criteria: * Inability to complete the informed consent comprehension process * Under 18 years of age * Does not speak English * Received diagnosis or testing result less than two months prior to study enrollment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Frontotemporal degeneration are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Medical Institution
Baltimore, Maryland, 21287, United States
-
National Institutes of Health (NIH)
Bethesda, Maryland, 20892, United States
-
University of Pennsylvania (Penn Frontotemporal Degeneration Center)
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Spinal injection drug targets genetic cause of ALS and dementia
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Could a brain disease change behavior years before diagnosis?
- Smart bracelets could read the hidden signs of apathy in dementia
- Can a synthetic cannabinoid calm agitation in frontotemporal dementia?